SMX has developed a technology that embeds invisible molecular markers into gold, creating a persistent digital identity linked to a secure record of the gold's origin, composition, and chain of custody. This innovation addresses growing investor demand for trustworthy physical assets as gold prices rise due to economic uncertainty and geopolitical risks. The molecular ID remains with the gold through refining, manufacturing, and recycling, enhancing provenance verification and supply chain transparency. SMX's trueGold platform aims to provide continuous traceability from mine to market, supporting responsible sourcing and confidence in gold holdings worldwide.
SMX and its gold technology provide context for market activity. For readers following Pluang's broader market, as of Oct 07, 2026 01:51 WIB, 96 of 150 US stocks rose while 54 fell. Notable movers include Nokia at USD 10.86 with a 6.42% increase and a typical hold time of 66 days, Moderna at USD 190.40 down 6.30%, and BlackBerry at USD 9.59 up 5.62%.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
